BRAF and melanoma: Thus, overexpression of USP22 resulted in resistance to the BRAF inhibitor vemurafenib through the stabilization of YAP and opened new therapeutic avenues for combined inhibition of USP22/YAP and BRAF as an option for melanoma treatment [67].